Anbio Biotechnology (NNNN)

Anbio Biotechnology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	2.37	2.25	10.01	2.54
Depreciation & Amortization	-	0.01	0.01	-
Loss (Gain) From Sale of Investments	-0.34	-0.16	-0.04	-
Change in Accounts Receivable	0.82	-1.88	0.72	-0.72
Change in Inventory	-	0.35	-0.35	-
Change in Accounts Payable	0.8	-0.58	-0.48	1.89
Change in Other Net Operating Assets	-1.57	0.91	-5.41	0.47
Operating Cash Flow	2.08	0.9	4.45	4.18
Operating Cash Flow Growth	131.57%	-79.81%	6.40%	-
Investment in Securities	0.34	1.73	-1.53	-
Investing Cash Flow	0.34	1.73	-1.53	-
Other Financing Activities	-0.34	-0.04	-	-
Financing Cash Flow	-0.34	-0.04	-	-
Net Cash Flow	2.07	2.59	2.92	4.18
Levered Free Cash Flow	1.27	0.03	0.87	-
Unlevered Free Cash Flow	1.27	0.03	0.87	-
Change in Net Working Capital	-0.03	1.21	5.51	-

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q